Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

DUROS technology delivers peptides and proteins at consistent rate continuously for 3 to 12 months.

Rohloff CM, Alessi TR, Yang B, Dahms J, Carr JP, Lautenbach SD.

J Diabetes Sci Technol. 2008 May;2(3):461-7.

2.

Chronic (60-week) toxicity study of DUROS leuprolide implants in dogs.

Cukierski MJ, Johnson PA, Beck JC.

Int J Toxicol. 2001 Nov-Dec;20(6):369-81.

PMID:
11797819
3.

An in vivo/in vitro comparison with a leuprolide osmotic implant for the treatment of prostate cancer.

Wright JC, Tao Leonard S, Stevenson CL, Beck JC, Chen G, Jao RM, Johnson PA, Leonard J, Skowronski RJ.

J Control Release. 2001 Jul 10;75(1-2):1-10.

PMID:
11451492
4.

Critical variables associated with nonbiodegradable osmotically controlled implants.

Wright JC.

AAPS J. 2010 Sep;12(3):437-42. doi: 10.1208/s12248-010-9199-8. Epub 2010 May 19. Review.

5.

Leuprorelin implant (ALZA). DUROS, leuprolide acetate implant, leuprolide implant, Viadur.

[No authors listed]

Drugs R D. 1999 Dec;2(6):425-6. No abstract available.

PMID:
10763458
6.

DepoFoam technology: a vehicle for controlled delivery of protein and peptide drugs.

Ye Q, Asherman J, Stevenson M, Brownson E, Katre NV.

J Control Release. 2000 Feb 14;64(1-3):155-66.

PMID:
10640654
7.

Characterization and comparison of leuprolide degradation profiles in water and dimethyl sulfoxide.

Hall SC, Tan MM, Leonard JJ, Stevenson CL.

J Pept Res. 1999 Apr;53(4):432-41.

PMID:
10406221
8.

Managing advanced prostate cancer with Viadur (leuprolide acetate implant).

Moul JW, Civitelli K.

Urol Nurs. 2001 Dec;21(6):385-8, 393-4; quiz 395-6. Review.

PMID:
11998504
9.

Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature.

Brocklebank D, Ram F, Wright J, Barry P, Cates C, Davies L, Douglas G, Muers M, Smith D, White J.

Health Technol Assess. 2001;5(26):1-149. Review.

10.

Evaluation of an implant that delivers leuprolide for 1 year for the palliative treatment of prostate cancer.

Fowler JE, Flanagan M, Gleason DM, Klimberg IW, Gottesman JE, Sharifi R.

Urology. 2000 May;55(5):639-42.

PMID:
10792069
11.

Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?

Cox MC, Scripture CD, Figg WD.

Expert Rev Anticancer Ther. 2005 Aug;5(4):605-11. Review.

PMID:
16111462
12.
13.

Protein delivery with infusion pumps.

Bremer U, Horres CR, Francoeur ML.

Pharm Biotechnol. 1997;10:239-54. Review.

PMID:
9160375
14.

Stability of poly(D,L-lactide-co-glycolide) and leuprolide acetate in in-situ forming drug delivery systems.

Dong WY, Körber M, López Esguerra V, Bodmeier R.

J Control Release. 2006 Oct 10;115(2):158-67. Epub 2006 Jul 20.

PMID:
16963145
15.

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.

Nauck MA, Wollschläger D, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Willms B.

Diabetologia. 1996 Dec;39(12):1546-53.

PMID:
8960841
16.

High-technology i.v. infusion devices.

Kwan JW.

Am J Hosp Pharm. 1989 Feb;46(2):320-35. Review.

PMID:
2653027
17.

MEMS fabricated chip for an implantable drug delivery device.

Sbiaa Z.

Conf Proc IEEE Eng Med Biol Soc. 2006;1:5621-4.

PMID:
17947154
18.

Microsphere delivery of Risperidone as an alternative to combination therapy.

D'Souza S, Faraj J, DeLuca P.

Eur J Pharm Biopharm. 2013 Nov;85(3 Pt A):631-9. doi: 10.1016/j.ejpb.2013.07.012. Epub 2013 Jul 24.

PMID:
23892159
19.

Menses induction and second-trimester pregnancy termination using a polymeric controlled release vaginal delivery system containing (15S)15-methyl PGF2 alpha methyl ester.

Bygdeman M, Christenssen N, Gréen K, Vesterqvist O, Roseman TJ, Tuttle ME, Spilman CH.

Contraception. 1983 Feb;27(2):141-51.

PMID:
6303690

Supplemental Content

Support Center